AKT1 and urinary bladder carcinoma: Functionally, CL4 was enriched in canonical cancer pathways, including hepatocellular carcinoma, gastric cancer, small cell lung, prostate, and bladder cancers, as well as in key signaling pathways such as PI3K–Akt and AMPK (Figure 5b).